News & Events

Viveve(R) Treatment Now Available in 6 Countries in Europe

SUNNYVALE, CA -- (Marketwired) -- 04/09/15 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced a new distribution partnership with Dalton Medical, B.V. ("Dalton Medical"), a distributor of medical devices based in Oosterhout, Netherlands. The agreement, which covers the Netherlands, Belgium and Luxembourg, combines Dalton Medical's strong presence in the medical device market throughout the region with Viveve's innovative product for treating vaginal laxity. The Viveve® Treatment is now available throughout the United Kingdom, Ireland, Spain, Netherlands, Belgium and Luxembourg.

"Our partnership with Dalton Medical will provide us with a strong foothold in this important region and assist in greatly expanding the availability of the Viveve® Treatment," said Patricia Scheller, the Chief Executive Officer of Viveve. "We believe that the clinically demonstrated safety and efficacy profile of this painless procedure make the Viveve Treatment the best alternative for treating a condition that can profoundly impact a woman's sexual satisfaction and quality of life."

Dalton Medical, a distributor of innovative medical technologies and products in Belgium, the Netherlands and Luxembourg, has established an excellent reputation in the medical, aesthetic and surgical markets. Due to its extensive range of products and broad market scope, Dalton Medical provides its customers with the convenience of obtaining the best solutions from a single partner.

"We are thrilled to be able to bring such an advance in women's sexual health to the Benelux region," said Niels Tanja, Director of Dalton Medical. "This is a market with great potential and we anticipate that a single non-surgical treatment for a condition that affects so many women will be well-received by physicians and women alike."

About Viveve

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.

We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

 

Contact:

Amato and Partners, LLC

Investor Relations Counsel

90 Park Avenue. 17th Floor

New York, NY 10016

212.430.0360

admin@amatoandpartners.com

 

Source: Viveve Medical, Inc.

Released April 9, 2015